Wird geladen...

Food and Drug Administration Perspective on Negative Symptoms in Schizophrenia as a Target for a Drug Treatment Claim

Negative symptoms of schizophrenia are not adequately addressed by available treatments for schizophrenia. Thus, it is reasonable to consider them as a target for a drug claim. This article describes the thought process that the Food and Drug Administration (FDA) will undertake in considering negati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Laughren, Thomas, Levin, Robert
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2006
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2632229/
https://ncbi.nlm.nih.gov/pubmed/16079389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/schbul/sbi039
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!